Tony Maschio has co-authored an article for Bloomberg BNA’s Life Science’s Law & Industry Report. The article, titled “Is Mayo v. Prometheus the End of Diagnostic Patents?,” examines the potential impact of the United States Supreme Court’s March 2012 decision that a method for adjusting a drug dosage after observing a patient’s reaction to a drug administration was patent-ineligible subject matter. The authors provide both U.S. and European considerations of the unanimous ruling, ultimately asserting that Prometheus does not spell the end of diagnostic patents.
Published by Bloomberg BNA, the Life Sciences Law & Industry Report provides biweekly updates on current regulatory, legislative, and legal issues affecting the many disciplines that make up the burgeoning life sciences industry.
To read the article click here.